Ohio State Navbar

Directory

Yvonne Efebera, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-2268

Email: efebera.1@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Biographical

I am currently an Assistant Professor of Medicine in the Clinical Scholar track in the Division of Hematology at The Ohio State University (OSU). I earned my MD degree from the Pennsylvania State University and completed residency in Internal Medicine at Cleveland Clinic. After three years of practicing as an Internist, I decided to pursue further training in hematology/Oncology at Boston University and training in Blood and Marrow Transplantation (BMT) at MD Anderson Cancer Center before joining OSU in August 2009 where I am also involved in the BMT program. My special research interests are in Multiple Myeloma, Amyloidosis and Graft-versus-Host-disease (GVHD).

Since joining OSU, I have been actively involved in research, leading three active investigator initiated studies, and being the institutional PI for several National Cancer Institute (NCI) and National Corporate group sponsored Trials. My first investigator initiated phase II trial “evaluating the safety and efficacy of atorvastatin for the prophylaxis of acute graft-versus-host disease (GVHD) in patients with hematological malignancies undergoing HLA-matched sibling donor allogeneic hematopoeitic stem cell transplant (HSCT)”, funded by the division of hematology, completed accrual of 40 patients-donor pairs in under two years as of January 31 2014. Patients are currently being followed for endpoint assessments. Abstracts from this study have been presented in Oral and poster forms at the International meeting of the American Society of hematology (ASH) 2012 and the American Society of Blood and Marrow Transplant (ASBMT) 2013. We hope to use the findings of this study to propose a comparison study using standard controls from the Center for International Blood and marrow transplant (CIBMTR) data. This work also holds great promise in that it could lead to a Phase III study through the Blood and marrow Transplant/Clinical Trials Network (BMT/CTN) collaborative group evaluating standard GVHD prophylaxis with and without atorvastatin in patients undergoing HSCT and could also extend to solid organ transplantation. The second Investigator Initiated trial “Assessment of Micro-RNA’s in acute graft-versus-host-disease (aGVHD)” sponsored by the national Heart and Lung and Blood Institute (NHLBI) opened in April 2012, and has accrued 240 patients who are undergoing allogeneic HSCT. Dr. Garzon and I proposed to prospectively evaluate the microRNA expression profile of adult patients undergoing allogeneic HSCT. Weekly samples up to day 100 of HSCT are being collected with extraction of serum, plasma and mononuclear cells. This study holds great promise in investigating the role of microRNAs in the pathogenesis of acute GVHD, which may lead to the development of safer and more effective GVHD prophylactic and treatment strategies for HSCT patients. Three Poster and Oral abstracts have been presented at the European hematology Association (EHA 2013) ASH 2013 and EHA 2014. The third Investigator initiated trial “phase II study of CT-011( a program-death -1 inhibitor) with lenalidomide in relapse multiple myeloma”, sponsored by the American Cancer Society (ACS) opened March 1, 2014 with cohort 1 completely filled by the first wk. A fourth Investigator initiated trial “AR42 (a histone deacetylase) with pomalidomide in relapse and refractory multiple myeloma “partly sponsored by Celgene, is in the protocol phase. These will lead to First and senior Author Publications.

I am the local PI for the BMT/CTN 0702 study “A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma” that closed 6 months ahead of schedule due to OSU being the lead accruing center of 64 patients. In addition, I am the local PI for the BMT/CTN study “A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age”; The NCI Cancer and Leukemia group B ( CALGB also known as Alliance) A061202 study “A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy”; and a first in man study “A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001in Patients Undergoing Allogeneic HSCT. An ALLIANCE sponsored study as co-PI “phase II study with Ibrutinib with lenalidomide in relapse multiple myeloma” is in the initial phase of development. I am on the protocol team for the next BMT/CTN study for allogeneic SCT in MM “BMT CTN 1302 A Multicenter Phase II, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma”. Dr. Garzon and I are collaborating with the University of Michigan on a database and biorepository for aGVHD- The “Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository”. The MAGIC Study will collect 500 patient samples a year for current and future studies on biomarkers for GVHD. In addition to being the PI on these studies, I am co-investigator in many studies in multiple myeloma and in BMT.


Since 2010, I have been involved in teaching medical students, residents and fellows. I am a participant in the Clinical Assessment and Problem Solving (CAPS) longitudinal program, having two first year medical students for the first 2 years of medical school in clinic monthly. Students learn how to perform complete physical exam, taking a complete history, doing vitals, and doing a brief visit exam (SOAP note). I am involved in having 3rd and 4th year medical students do monthly rotations in my clinic learning about diagnosis and treatment of multiple myeloma (MM), amyloidosis and learning the process of Blood and marrow transplant (BMT). Residents from all levels do monthly rotations, and fellows do 3 months blocks, all with the goal of enhancing student/residents/fellows education, communication with patients, diagnosis and treatments of patients with multiple myeloma, amyloidosis and BMT. I am involved in the first and second year medical students lecture series in MM and Amyloidosis and patient interview and discussions. I participate in resident’s lectures during the lecture series, presenting didactics with clinical presentations, diagnosis and managements of MM, amyloidosis and basics and principles of BMT. I have been a research mentor for 2 residents, 2 fellows and one medical student. This has resulted in 4 manuscript, one that has been published, 2 that have been submitted for publication and the forth that is under review. Seven abstracts have also resulted from my mentorship, presented in Poster and oral forms at ASH, ASBMT, The International Myeloma Working Group (IMW, France), and the European Society of Blood and Marrow Transplantation meetings (EBMT). One resident received the ASH travel award. I have been an invited speaker at grand rounds locally and State wise. I am involved with nursing education and lecture series and actively involved in giving talks to undergraduate students and patients in different support groups (e.g. leukemia lymphoma society, multiple myeloma opportunities for research and education) in MM, amyloidosis and BMT.

I have been very fortunate to serve on national and International NCI sponsored committees in MM and in BMT. I am the OSU representative on the MM committee of the NCI sponsored CALGB, the BMT/CTN committee for the BMT/CTN 0702 study, the International Amyloidosis End-point/Adjudication Committee for Millenium-Takeda C16011 International amyloidosis study, the multiple myeloma research foundation committee and the GVHD committee for ASBMT and ASH. I have moderated oral abstract session at ASH in transplantation; A national Medical ED forum on clinical dialogue in myeloma and the role of transplant in the era of novel agents; and media Interview on update in research for Graft-versus-Host-Disease. I have contributed to the American Society of Clinical Oncology (ASCO) educational Book being first author on the topic “Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia: Who Should Be Transplanted in First Complete Remission”. In addition, I have been invited to write the chapter on “Classification and clinical manifestations of lymphocyte and plasma cell disorders” on the 9th edition of Williams Hematology a well-known and routinely used hematology textbook.; and have received an invitation to speak and participate in an international forum on the “Annual Summit on Practical and Emerging Trends in Multiple Myeloma and chronic lymphocytic leukemia” in whistler, Canada. I am also fortunate to be invited to write a commentary in the international high impact Journal BLOOD. I review for several journals including BLOOD Journal, Cancer Journal, Clinical Advances in Hematology and Oncology, Biology of Blood and Marrow Transplantation, British Journal of Haematology, Bone Marrow Transplant and Leukemia and Lymphoma. Locally at OSU, I am a member of the Ethics Committee, the BMT translational research committee, the search committee for the director of palliative care, the Multiple Myeloma Opportunities for Research and Education (MMORE) committee and the chair of the BMT GVHD committee. I was a member of the medical Staff advisory committee for one year 2010-2011, and I’m involved in the interview process of medical students for the Internal Medicine residency program. I am currently enrolled in the Masters of Public Health program- to finish in December 2014.
I am the recipient of several grants-The National Institute of Health (NIH) Loan repayment program, an NHLBI R21 grant (with Dr. Ramiro Garzon), an ACS grant (with Dr. Don Benson), A K12 institutional grant; and an institutional CCTS grant. I have applied for a pelotonia grant to assist in one of my investigator initiated trials. A Program Project grant is planned to be submitted in May 2014 for the MAGIC study in collaboration with The University of Michigan. In addition I have applied for several grants including the NIH K23, ASBMT, ASH, CALGB, ASCO, and The Harold Amos Medical Faculty Development Program.

In Summary, in my first 4 years here on staff, I am happy to say that I have been productive in teaching, mentoring, research and service. My mentors Dr. Steven Devine, program director of the blood and marrow program at OSU, and Dr. John Byrd, director of the hematology program have been wonderful in providing me with the tools needed to succeed in academics. Meeting with Dr. Devine monthly has kept me focused and provided me with new ideas for new projects. I hope to continue in this path with more prospective studies publication.

Academic Advising

I was an ad hoc academic advisor to an OSU undergraduate student Selamawit Admasu, who spent time with me in the clinic and on the in-patient service. She is now a medical student at University of Kentucky College of Medicine. Part of my weekly tutorial of high school students is also spent on advising. I have been a research mentor for 2 residents, 2 fellows and one medical student. This has resulted in 4 manuscript, one that has been published ( by former resident Neil Dunavin), 2 that has been submitted for publication (current fellow Benjamin Chu and former fellow Galena Salem) and the forth that is under review (current medical student Akshata Pandit) . Seven oral and poster abstracts have also resulted from my mentorship, presented at the American Society of Hematology (ASH), American Society of Blood and Marrow Transplantation (ASBMT), The International Myeloma Working Group (IMW), and the European Society of Blood and Marrow Transplantation meetings.

Continuing Education, Extension, and Other Courses Taught

I am involved in continued education and teaching of the medical students, Internal medicine residents and hematology/Oncology fellows.

Noteworthy Graduate Narrative

I have been a research mentor for 2 fellows, 2 residents and one medical student. Dr. Galena Salem, who is currently in private practice, presented 2 abstracts, an oral at the European Blood and Marrow Transplant 2012 meeting entitled “Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity”, and a poster at the 2013 American Society of Blood and Marrow Transplant entitled “Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)”. Her manuscript on this work has been summited for publication. Dr. Benjamin Chu, a current second year fellow, presented his poster abstract “Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome” at the International Amyloid Workshop in Kyoto Japan 2013. This work has also been submitted for publication. Dr. Neil Dunavin a resident who is now a hematology/oncology fellow at the NIH, presented 2 poster abstracts “Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma” and “Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study” at the American Society of Hematology meeting 2010 and the International Myeloma meeting in France 2011. Dr. Dunavin won an ASH travel award and has published this work in Leukemia and Lymphoma Journal. Dr. Habib, who was also a resident, was co-author on these abstracts. Akshata Pandit, a current third year medical student presented her abstract “Autologous Hematopoietic Stem Cell Transplant (HSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)” at the 2013 American Society Of Blood and Marrow Transplantation (ASBMT) Annual Meeting, and the manuscript is currently in preparation.

Clinical Interest

Hematology;Medical Oncology

Academic Advising

2011 - present , The Ohio State University.
2012 - present Akshata Pandit, The Ohio State University. Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL Amyloidosis)
2013 - present Benjamin Chu, The Ohio State University. Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome
2016 - present , The Ohio State University.
2015 Sara Singer, The Ohio State University. Graduated 0.
2010 - 2012 Neil Dunavin, The Ohio State University. Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma; Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study.
2011 - 2012 Selamawit Admasu, The Ohio State University. Graduated 2013.
2011 - 2012 Joyce Habib, The Ohio State University. Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation; Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma.
2012 - 2013 Galena Salem, The Ohio State University. Graduated 2013. Lower Dose of Antithymocyte Globulin (ATG) decreases bacterial infection without Increasing Graft-vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant ( allo HSCT); 2.Busulfan, Cyclophosphamide, Etoposide is Not Superior to Carmustine, Etoposide, Cytarabine, Melphelan Conditioning Prior to Autologous Stem Cell Transplantation n Patients with Hodgkin Lymphoma & is Associated with increase toxicity
 

Licenses

2000 - present State of Ohio Medical Board: State Medical Board of Ohio
2002 - present Board Certified: American Board of Internal Medicine
2008 - present Board Certified: American Board of Internal Medicine
 

Chapters in Books

Hematopoietic Stem Cell Transplantaion for Acute Myelogenous Leukemia: Who should be Transplanted in First complete remission?.

 

Clinical Services

09/01/2009 Hematology (HEM) I In Patient Service (James Cancer Hospital, Hematology)
10/01/2009 Bone Marrrow Transplant (BMT) In Patient Service (James Cancer Hospital, Hematology)
10/01/2009 Multiple Myeloma Outpatient Clinic (2nd Floor James Cancer Hospital)
12/01/2011 Hematology (HEM) 3 In-Patient Service (James Cancer Hospital, Hematolgy)

Conferences

Autologous peripheral stem cell transplantation for multiple myeloma in a patient with a 10 year-old kidney transplant: Case report and clinical issues

CD40 ligand activation alters B cell migration to secondary lymphoid organs.

Primary antigen-specific B cells: A novel approach to cellular-based immunotherapy.

T(H)17 pathway and associated pro-inflammatory cytokines promote immune dysfunction in myeloma

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application.

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CRI) Post Induction Chemotherapy: a Retrospective Case Control Study.

Complete Response to Thalidomide and Dexamethasone in a patient with Necrobiotic Xanthogranuloma (NXG) associated with Monoclonal Gammopathy of Uncertain Significance (MGUS)

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma

Impact of Pre-stem Cell Transplant Ferritin Levels on late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Outcomes

IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma

Lack of Response to Vaccination in MGUS and Stable Myeloma

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma

Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.

Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study

Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma

A phase I study of IPH2101, a novel anti-inhibitory monoclonal antibody, in patients with multiple myelonia

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

Results of employing a plerixafor dosing algorithm to mobilize hematopoietic stem cells in patients with multiple myeloma and lymphoma

Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities

Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study.

Renal amyloidosis associated with a novel fibrinogen A alpha chain mutation

Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma

miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients

Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)

Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma

Hereditary gelsolin amyloidosis: a novel variant N211K, and a review of the clinical, histological and SAP scintigraphic characteristics

BUSULFAN, CYCLOPHOSPHAMIDE, ETOPOSIDE (BUCYVP) OR CARMUSTINE, ETOPOSIDE, CYTARABINE, MELPHELAN (BEAM) FOR CONDITIONING PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH HODGKIN LYMPHOMA (HL)?

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Serum miR-29a is up-regulated in acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo HSCT) and activates dendritic cells (DCs)

Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)

A Phase 1 Trial of Reolysin Alone in Patients with Refractory or Relapsed Multiple Myeloma

Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome.

. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma

Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Blood

Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)

Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)

Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome

Tocilizumab In The Treatment Of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience

Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) in Lenalidomide-Refractory and Proteasome Inhibitor-Exposed Myeloma: The Phase 1 MM-005 Trial

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL

MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

SERUM MIR-29A IS UP-REGULATED IN ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) AND ACTIVATES DENDRITIC CELLS (DCS)

T-Cell p16(INK4A) Expression Increases Post-Transplant in Patients with Multiple Myeloma

Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

ADDITIONAL PROGNOSTIC VALUE OF CIRCULATING MIR-16 EXPRESSION OVER THE USUAL PROGNOSTIC PARAMETERS IN MULTIPLE MYELOMA PATIENTS

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT)

miR-155 affects T cell migration in acute Graft Versus Host Disease (aGVHD)

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report

MiR-155 Impacts T Cell Migration in Acute Graft-Versus Host-Disease (aGVHD)

A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts

A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN'S LYMPHOMA

Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Long Term Lenalidomide and Dexamethasone Therapy Without Autologous Stem Cell Transplant (ASCT) in a patient with POEMS Syndrome

Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) in Lenalidomide-Refractory and Proteasome Inhibitor-Exposed Myeloma

 

Degrees

1994 B.S., University of The District of Columbia

1998 M.D., The Pennsylvania State University College of Medicine

2014 M.Public Hlth., The Ohio State University

 

Editorial Activities

2009 - present Cancer Journal
2010 - present Bone Marrow Transplant
2010 - present Biology of Blood and Marrow Transplantation
2010 ASCO Educational Book 2010
2012 - present Clinical Advances in Hematology and Oncology
2013 - present Leukemia and Lymphoma
2014 - present Blood Journal
2014 - present British Journal of Haematology
2014 - present Williams Hematology, 9th Edition
 

Honors

1990 - 1994 Dean's List.
1991 The William Curtis Award for Outstanding Junior in Chemistry. ..
1991 - 1994 Participant of the Honors Undergraduate Research Training Program. NIH-MARC (National Institute of Health-Minority Access to Research Careers).
1991 - 1994 Beta Kappa Chi National Scientific Honor Society.
1994 The American Chemical Society award for best graduating senior in Chemistry. The American Chemical Society.
2007 VA Boston Healthcare System Golden Heart Award for Outstanding Service. VA Boston Healthcare System.
2009 - 2013 K12 Translational Training Grant in Experimental Therapeutics. National Institute of Health (NIH).
2010 - present Recognition for teaching medical students and Participating in CAPS. Internal Medicine Department.
2011 West Virginia WVCTSI Ohio State CCTS Partnership Pilot Award. West Virginia WVCTSI.
2012 - present Featured Story in "Journey to Innovation". The Ohio state University.
 

Journal Articles

.

 

Reference Works

January 2006 Efebera Y, Ahmadi T, Sherr D."CD40 ligand activation alters B cell migration to secondary lymphoid organs" .
January 2006 Ahmadi T,Weizmann N, Efebera Y, Sherr D."A novel approach to cellular based immunotherapy" .
January 2007 Prabhala R, Pelluru D, Neri P, Fulciniti M, Driscoll J, Weihua S, Blotta S, Yu-Tzu Tai, Patel H,Efebera YA, Hideshima T, Chauhan D, Daley JF, Anderson KC, Munshi NC."TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma" .
January 2008 Prabhala R, Pelluru D, Fulciniti M, Nanjappa P, Prabhala HK, Prabhala NS, Mitsiades C, Tai Y-T, Ghobrial I, Richardson P, Lefkimmiatis K, Daley JF, Efebera YA, Anderson KC, Munshi NC.."TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application." . : abstract # 2737
January 2008 Efebera YA, Kantarjian HM, Anderson B, Pierce S, De Padua Silva L, Ravandi F, Giralt SA, Borthakur G, Champlin R, De Lima M."Allogeneic Hematopoietic Stem Cell Transplant (HSCT) versus Conventional Chemotherapy in patients with Acute Myelogenous Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) attaining complete remission (CR1) post induction chemotherapy: A retry" .
January 2008 Efebera Y, Blanchard E, Allam C, Andrew Han, Munshi N."Complete Response to Thalidomide and Dexamethasone in a patient with Necrobiotic Xanthogranuloma (NXG) associated with Monoclonal Gammopathy of Uncertain Significance (MGUS)" .
January 2009 Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A., Hosing C, Ledford M, Champlin R, Giralt S."Impact of Pre-stem Cell Transplant Ferritin Levels on late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Outcomes" .
January 2009 Benson D, Bakan CE, Alghothani L, Hofmeister CC, Efebera YA, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, Caligiuri MA, Devine SM."Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma" .
January 2009 Prabhala RH,Efebera, YA, Han AJ, Pelluru D, Nanjappa P, Amin S, Pai C, Ghobrial I, Schlossman RL, Laubach J, Fulciniti M, Richardson P, Anderson KC, Munshi NC."Lack of Response to Vaccination in MGUS and Stable Myeloma" .
January 2009 Hofmeister CC, Benson D, Farag S, Grever MR. Efebera YA."Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma." .
January 2010 Dunavin N, Habib J, Phillips G, Elder P, Tranovich M, Benson DM, Hofmeister C, Byrd JC, Devine SM, Efebera YA."Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma." .
November 2010 Neil Dunavin, Joyce Habib, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Jr., Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera.."Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma." . : abstract #3564
November 2010 Craig C. Hofmeister, Gisele Rieser, Mindy A Bowers, Lisa C Merritt, Carli N Greenfield, Yvonne A Efebera, Don M Benson, Jr., Steven M Devine, and Janet S de Moor."Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors." .
November 2010 Benson, Jr DM, Bakan CE, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera YA, Blanchet S, Caligiuri MA, Farag S."IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data." .
January 2010 Habib J, Dunavin N, Phillips G, Elder P, Tranovich M, Benson DM, Hofmeister CC, Byrd JC, Devine SM, Efebera YA."Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study" .
January 2010 Munshi NC, Lee S, Kambhampati S, Mohiuddin A, Rose M, Behler C, Han A, Efebera YA, Houranieh A, Brophy MT, Zimelman A, Prabhala RH, Saba HI, Klein C, Mehta P, Hayes T, Roodman D, Lichtenstein AK."Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities" .
November 2010 Joyce Habib, MD, Neil Dunavin, MD, Gary Phillips, MAS, Patrick Elder, MS, Meaghan Tranovich, Don M Benson, Jr., MD, Craig C. Hofmeister, MD, John C. Byrd, MD, Steven M. Devine, MD, Yvonne Efebera, MD.."Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. Blood." . : abstract #1343
January 2010 Benson DM, Padmanabhan S, Hofmeister CC, Bakan CE, Abonour R, Suvannasankha A, Efebera Y, Squiban PJ, Caligiuri MA, Farag S."A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma" .
November 2011 Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Michal Rose, Abid Mohiuddin, Yvonne Efebera, Andrew Han, Antoun Houranieh, Abraham Zimelman, Mary T. Brophy, Rao Prabhala, Terrence Grady, Paulette Mehta, Teresa G Hayes, Sarvari Venkata Yellapragada, Caroline Behler, Catherine Klein, David Roodman, Alan K. Lichtenstein.."Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities" . : Abstract #3964
November 2011 Simrit Parmar, Gabriela Rondon, Peter F Thall, Roland Bassett, Marcos De Lima, Chitra M Hosing, Paolo Anderlini, Partow Kebriaei, Issa Khouri, Prasanth Ganesan, Yvonne A Efebera, Richard Champlin, and Sergio A Giralt.."Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens" . : abstract #1944
February 2012 Salem, G., Ruppert, A. S., Efebera, Y., Elder, P., Bingman, A., Penza, S., Andritsos, L. A., Devine, S. M.."Busulfan, cyclophosphamie, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)" . : S246
April 2012 Galena Salem, Neil Dunavin, Lai Wei, Pat Elder, Sam Penza, Kristie Blum, Pierlugi Porcu, Robert Baiocchi, Jeffrey Jones, Joseph Flynn, Leslie Andritsos, Steven M Devine, Beth Christian, Yvonne Efebera."Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxici" .
Yvonne A. Efebera, Dorota Rowczenio , Anjali Satoskar, Don M. Benson, Tibor Nadasdy, Philip N. Hawkins F."Renal amyloidosis associated with a novel fibrinogen A alpha chain mutation." .

Softwares

November 2013 Yvonne A. Efebera."Multiple Myeloma; Diagnosis and Treatment"
December 2013 Yvonne A. Efebera."Update in Research and Graft-versus-Host-Disease"

Presentations

Lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk Myelodysplastic syndromes with karyotypes other than deletion 5q

Highlights in Hematology

Update on Primary Amyloidosis

Update on Multiple Myeloma and Treatment

Myeloma Update

OSU Fellows Board Review

American Society of Hematology Review - on multiple Myeloma, Amyloidosis and Transplant

American Society of Hematology Oral Abstract Session

Managing Myeloma: clinical dialogue in myeloma, what is the role of transplant in the era of novel agents?

Cancer Awareness Concert and Fundraiser

Multiple Myeloma Updates

Multiple Myeloma and Plasma cell Dyscrasisas

Review of Abstracts, Poster Discussion Session

 

Professional Activities

2014 - present Blood Marrow Transplantation Clinical Trial Network.
2014 - present Adjudication Committee for BMT/CTN.
2015 - present Speaker’s Bureau. Takeda Pharmacerutical.
2009 MMORE. Multiple Myelomia Opprotunities for Research and Education. Columbus, OH.
2012 International Amyloidosis Adjudication Committee. Millennium-Takeda.
2013 Research and Education. Multiple Myeloma Opportunities for Research and Education (MMORE).
2013 Michigan State acute GVHD International Consortium (MAGIC) study.
2002 - 2004 Bioethics Committee and Diversity Board, Member. Kaiser Permanente Integrated Managed Care Consortium.
2004 - 2008 Committee of Interns and Residents (CIR), Member. Boston University Medical Center.
2005 - 2008 Board of Trustees, Member. Preferred Home Health Care.